The relationship between repetitive behaviors and growth hormone response to sumatriptan challenge in adult autistic disorder.

What Was Tested

This randomized controlled trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

Autism is heterogeneous with respect to clinical symptoms and etiology.

To sort out this heterogeneity in autism, the researchers investigated whether specific neurobiological markers vary in parallel to core symptomatology.

Who Took Part

PubMed indexes the participants as teenagers, adults and middle-aged adults.

How the Study Was Run

The design is described as randomized, placebo-controlled and parallel-group.

The participants were allocated by chance, so the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) group and the comparison group should start out alike.

The comparison arm used a placebo, so changes seen with Exogenous HGH, sermorelin & older GHRPs (why they're passed over) could be set against what happens without it.

Groups ran in parallel: each of the participants stayed in one arm throughout.

What Was Measured

Specifically, the researchers assessed growth hormone response to the 5-HT 1d agonist, sumatriptan, and linked this measure of serotonergic function to the severity of repetitive behaviors in adult autistic patients.

The subject headings attached to it are Autistic Disorder, Compulsive Behavior, Human Growth Hormone, Psychiatric Status Rating Scales, Receptor, Serotonin, 5-HT1D, Receptors, Serotonin and Regression Analysis.

What This Means in Plain Language

The paper is a randomized, placebo-controlled and parallel-group study of Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

The publication is from 2000 (Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology), a journal based in England.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.